Overview

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Status:
Completed
Trial end date:
2015-12-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Selonsertib